A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Every year, there’s a new lineup of such curious clinical conditions. There are always some unfortunate souls to mark medical ...

Prevalence of Electrolyte Disorders in Oncology: Descriptive Cross-Sectional Study in the Cancer Department of the National ...

Al-Gahtani, S. (2026) Review of Literature Investigating the Correlation between Prevalence of Risk Factors Associated with ...